Core Points - OneMedNet Corporation has received a notice from Nasdaq indicating non-compliance due to the failure to timely file its Form 10-Q for the fiscal quarter ended September 30, 2024 [1] - Nasdaq previously granted an exception until December 11, 2024, for the company to file delinquent reports for the quarterly periods ended March 31, 2024, and June 30, 2024 [2] - The company is actively working to complete the delinquent filings and aims to regain compliance with Nasdaq Listing Rules [3] - The notice does not have an immediate effect on the listing of the company's common stock or warrants on Nasdaq [4] Company Overview - OneMedNet Corporation is a global provider of clinical imaging innovation and manages regulatory-grade Imaging Real World Data (iRWD™), which includes electronic health records and medical imaging [1][5] - The company's iRWD™ platform supports diverse clinical data management, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and medical imaging [5] - OneMedNet's platform addresses various clinical requirements across domains such as rare diseases, central nervous system disorders, oncology, cardiology, and women's health [6] - The company is committed to enhancing patient outcomes and supporting healthcare innovation through its research services [6]

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a pioneer in curating regulatory-grade Real World Data (RWD) including electronic health records, laboratory results, and medical imaging, has announced an additional strategic investment in Bitcoin. This investment is designed to enhance the company's financial resilience and support the expansion of its cutting-edge iRWD™ platform. As of November 12, 2024, the Company has invested in approxi ...

Core Insights - OneMedNet Corporation has announced a strategic refresh of its Board of Directors to enhance leadership and engagement as it transitions into a publicly traded entity [1][6] - The company expresses gratitude to former board members Paul Casey and Erkan Akyuz for their contributions during the IPO process [2] Board Member Profiles - Jair Clarke, an Executive Advisor at World Wide Technology and former Global CTO at Microsoft, joins the board to focus on market expansion, technology platform enhancement, and operational efficiency [3][4] - Sherry Coonse McCraw, former CFO of BMW North America, will lead the audit committee, emphasizing financial oversight, transparency, and human resources leadership [5] Company Overview - OneMedNet provides innovative solutions that leverage Real World Data (RWD) from over 1,400 healthcare systems, utilizing its proprietary iRWD™ platform for secure management of diverse clinical data types [7] - The platform supports various clinical domains, including rare diseases, oncology, and cardiology, aiming to enhance patient outcomes and drive healthcare innovation [8]

Core Points - OneMedNet Corporation has received notices from Nasdaq regarding its non-compliance with listing requirements due to the failure to timely file its Form 10-Q for the fiscal quarter ended June 30, 2024 [1][2] - Nasdaq has granted OneMedNet an extension until October 31, 2024, to file the delinquent filings and regain compliance [2] - The company is working with its new auditor to complete and file the delinquent filings as soon as possible, with an expectation to do so by the deadline [3] Company Overview - OneMedNet Corporation specializes in curating regulatory-grade Real World Data (RWD), including electronic health records, laboratory results, and medical imaging [1][5] - The company operates the iRWD™ platform, which manages diverse clinical data types and supports research opportunities for drug, medical device, and imaging/diagnostic AI development [5] - OneMedNet's platform is designed to meet clinical requirements across various domains, including rare diseases, oncology, and cardiology, aiming to enhance patient outcomes and drive healthcare innovation [6]

MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golde ...

Core Insights - OneMedNet Corporation has successfully integrated proprietary AI technology into its data curation process, enhancing the rapid and precise de-identification of patient data [1][2] - The integration of AI has significantly reduced operational costs and improved efficiency, allowing OneMedNet to process vast amounts of clinical data in minutes and deliver longitudinal clinical data and images to Life Science organizations up to five times faster than before [1][2] - OneMedNet's iRWD™ platform is recognized for managing diverse clinical data types, including electronic health records, laboratory results, and medical imaging, with AI enhancing the accuracy and speed of delivering regulatory-grade datasets [2][3] Company Overview - OneMedNet provides innovative solutions that unlock value from Real-World Data (RWD) repositories across over 1,400 healthcare system and provider sites within its iRWD™ network [3] - The company securely de-identifies, searches, and curates clinical data, offering research opportunities for drug, medical device, and imaging/diagnostic AI development customers [3] - OneMedNet's platform meets clinical requirements across various domains, including rare diseases, oncology, and cardiology, aiming to enhance patient outcomes and drive healthcare innovation [4]

Core Viewpoint - OneMedNet Corporation has successfully completed a private placement, raising approximately $4.6 million, which will be used for working capital and general corporate purposes, including a significant investment in Bitcoin [1][2][3]. Group 1: Private Placement Details - The private placement involved securities purchase agreements with institutional investors, including Off the Chain Capital and Discovery Capital Management [1]. - OneMedNet sold 1,297,059 shares at $1.0278 per share and prefunded warrants for 1,323,530 shares at the same price to Off the Chain Capital [2]. - The company also sold 2,301,791 shares at $0.85 per share to Discovery Capital Management [3]. Group 2: Use of Proceeds - The net proceeds from the private placement will primarily be allocated for working capital and general corporate purposes [1]. - The company has already utilized $1.8 million of the net proceeds to purchase Bitcoin [1]. Group 3: Company Overview - OneMedNet Corporation specializes in curating regulatory-grade Real World Data (RWD), including electronic health records, laboratory results, and medical imaging [6]. - The company operates the iRWD™ platform, which manages diverse clinical data types and supports research opportunities for drug, medical device, and AI development customers [6][7]. - OneMedNet's platform is designed to meet clinical requirements across various domains, including rare diseases, oncology, and cardiology [7].

MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Further to its press release dated June 14, 2024, OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, announced today that Cytel Inc, ("Cytel"), a global leader in clinical trial design and software, has now identified itself as the other party with which OneMedNet recently entered into a iR ...

Core Insights - OneMedNet Corporation has entered into a data license agreement with Cytel Inc, enhancing its capabilities in providing regulatory-grade Real World Data (RWD) for clinical trials [1][2] - The partnership aims to combine OneMedNet's extensive RWD repository with Cytel's advanced analytics, facilitating innovation in trial design and observational studies across various therapeutic areas [2][3] Company Overview - OneMedNet operates a proprietary iRWD™ network that includes over 121 million clinical exams from more than 31 million patients across 1,400 healthcare provider sites [2] - The company specializes in managing diverse clinical data types, including electronic health records, laboratory results, and medical imaging, to support drug and medical device development [5][6] Industry Context - Cytel is recognized as a leader in statistical software and advanced analytics for clinical trial design, with over 1,900 resources globally [4] - The collaboration is expected to enhance the capabilities of both companies in addressing significant health challenges, particularly in areas like oncology and neurologic disorders [3][6]

"This partnership aligns perfectly with OneMedNet's market expansion strategy, and significantly extends our commercial reach within the global life science industry," said Aaron Green, OneMedNet's President and CEO. "Our new partner's recognized expertise in clinical trial design and implementation, combined with our innovative RWD platform, creates a powerful synergy that should help accelerate the development of innovative new medical therapies and technologies targeting some of the world's greatest heal ...